OpenDNA has partnered with Blossom Family Medicine to introduce precision genetic testing into the primary care setting – making proactive, personalized risk assessment part of routine visits for patients.
Through this collaboration, Blossom Family Medicine will offer OpenDNA’s CardioRisk+, CancerRisk+, and TotalRisk+ genetic testing solutions, which helps assess individual risk for a range of chronic conditions, including heart disease, diabetes, and cancer.
These tests combine advanced polygenic risk scoring with clinical and family history analysis to deliver a more complete and personalized view of an individual’s health risks. These insights will be used by Blossom’s physicians to guide earlier, more informed prevention strategies tailored to each patient’s individual health risks.
“Partnering with OpenDNA aligns perfectly with our mission to deliver personalized, preventive, and patient-centered care,” said Dr. Jessica Marabella, Founder & Physician of Blossom Family Medicine. “By incorporating advanced, AI-driven genetic risk prediction into our practice, we’re empowering our patients with valuable insights to help guide their long-term health decisions.”
The precision testing will be integrated into Blossom’s routine care model, allowing physicians to receive and act on risk reports directly during appointments.
“This collaboration represents an exciting step forward in making precision medicine more accessible at the primary care level,” said Dr. Eran Feldhay, Founder and CEO of OpenDNA. “Blossom Family Medicine’s commitment to innovation and whole-family wellness makes them an ideal partner.” Patients who are interested in learning more about these new services or scheduling a consultation are encouraged to contact Blossom Family Medicine directly or visit www.blossomfamilymed.com.
